MRI and CT-guided radiation therapy for abdominopelvic sarcomas
Phase II Study of Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy for Abdominopelvic Sarcomas (MARS Trial)
PHASE2 · Jonsson Comprehensive Cancer Center · NCT06436612
This study tests if using MRI and CT scans to guide radiation therapy can help people with abdominopelvic sarcomas by targeting tumors more accurately while protecting healthy tissue.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 12 Years and up |
| Sex | All |
| Sponsor | Jonsson Comprehensive Cancer Center (other) |
| Drugs / interventions | radiation |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT06436612 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of MRI and CT-guided stereotactic body radiation therapy (SBRT) for patients with abdominopelvic sarcomas. Participants will receive radiation treatment daily for five consecutive days, followed by surgical removal of the primary tumor within 12 weeks. The approach aims to deliver precise radiation doses to tumors while minimizing exposure to surrounding healthy organs. The study will also involve careful planning and simulation to ensure optimal treatment delivery.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 12 and older with histologically confirmed sarcoma that is either primary or recurrent and resectable.
Not a fit: Patients with active treatment for another malignancy or a history of prior irradiation to the treatment area may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could improve tumor control and reduce side effects for patients with abdominopelvic sarcomas.
How similar studies have performed: Other studies have shown promising results with similar radiation therapy techniques, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed sarcoma * Primary or recurrent disease involving the abdomen or pelvis * Resectable primary lesion * Age ≥ 12 years old * Karnofsky performance status (KPS) ≥ 70 or Eastern Cooperative Oncology Group (ECOG) 0-2 * If a woman is of childbearing potential, a negative serum or urine pregnancy test must be documented Exclusion Criteria: * Active treatment of a separate malignancy * History of prior irradiation to the area targeted for treatment
Where this trial is running
Los Angeles, California
- UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California, United States (RECRUITING)
Study contacts
- Study coordinator: Christy Palodichuk
- Email: cpalodichuk@mednet.ucla.edu
- Phone: 3107942971
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Abdominopelvic Sarcomas